Select a medication above to begin.
Dupixent
dupilumab
Adult Dosing .
Dosage forms: INJ (pen): 200 mg per 1.14 mL, 300 mg per 2 mL; INJ (pre-filled syringe): 200 mg per 1.14 mL, 300 mg per 2 mL
atopic dermatitis, moderate-severe
- [300 mg SC every other week]
- Start: 600 mg SC x1 on day 1, then 300 mg SC every other week
moderate-severe eosinophilic asthma, maintenance tx
- [200 mg SC every other week]
- Start: 400 mg SC x1 on day 1, then 200 mg SC every other week; Alt: start 600 mg SC x1 on day 1, then 300 mg SC every other week
moderate-severe PO corticosteroid-dependent asthma, maintenance tx
- [300 mg SC every other week]
- Start: 600 mg SC x1 on day 1, then 300 mg SC every other week
moderate-severe PO corticosteroid-dependent asthma w/ concurrent moderate-severe atopic dermatitis, maintenance tx
- [300 mg SC every other week]
- Start: 600 mg SC x1 on day 1, then 300 mg SC every other week
moderate-severe PO corticosteroid-dependent asthma w/ concurrent chronic rhinosinusitis w/ nasal polyps, maintenance tx
- [300 mg SC every other week]
- Start: 600 mg SC x1 on day 1, then 300 mg SC every other week
chronic rhinosinusitis w/ nasal polyps, maintenance tx
- [300 mg SC every other week]
eosinophilic esophagitis
- [300 mg SC qwk]
prurigo nodularis
- [300 mg SC every other week]
- Start: 600 mg SC x1 on day 1, then 300 mg SC every other week
eosinophilic COPD, maintenance tx
- [300 mg SC every other week]
- Info: search 'gold' for epocrates COPD GOLD decision tools
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ (pen): 200 mg per 1.14 mL, 300 mg per 2 mL; INJ (pre-filled syringe): 200 mg per 1.14 mL, 300 mg per 2 mL
Special Note
- [formulation clarification]
- Info: pen form for use in pts 2 yo and older; pre-filled syringe form for use in pts 6 mo and older
atopic dermatitis, moderate-severe
- [6 mo-5 yo, 5-14 kg]
- Dose: 200 mg SC q4wk
- [6 mo-5 yo, 15-29 kg]
- Dose: 300 mg SC q4wk
- [6-17 yo, 15-29 kg]
- Dose: 300 mg SC q4wk; Start: 600 mg SC x1 on day 1, then 300 mg SC q4wk
- [6-17 yo, 30-59 kg]
- Dose: 200 mg SC every other week; Start: 400 mg SC x1 on day 1, then 200 mg SC every other week
- [6-17 yo, >60 kg]
- Dose: 300 mg SC every other week; Start: 600 mg SC x1 on day 1, then 300 mg SC every other week
moderate-severe eosinophilic asthma, maintenance tx
- [6-11 yo, 15-29 kg]
- Dose: 300 mg SC q4wk
- [6-11 yo, >30 kg]
- Dose: 200 mg SC every other week
- [12 yo and older]
- Dose: 200 mg SC every other week; Start: 400 mg SC x1 on day 1, then 200 mg SC every other week; Alt: start 600 mg SC x1 on day 1, then 300 mg SC every other week
moderate-severe PO corticosteroid-dependent asthma, maintenance tx
- [6-11 yo, 15-29 kg]
- Dose: 300 mg SC q4wk
- [6-11 yo, >30 kg]
- Dose: 200 mg SC every other week
- [12 yo and older]
- Dose: 300 mg SC every other week; Start: 600 mg SC x1 on day 1, then 300 mg SC every other week
moderate-severe PO corticosteroid-dependent asthma w/ concurrent moderate-severe atopic dermatitis, maintenance tx
- [6-11 yo, 15-29 kg]
- Dose: 300 mg SC q4wk; Start: 600 mg SC x1 on day 1, then 300 mg SC q4wk
- [6-11 yo, 30-59 kg]
- Dose: 200 mg SC every other week; Start: 400 mg SC x1 on day 1, then 200 mg SC every other week
- [6-11 yo, >60 kg]
- Dose: 300 mg SC every other week; Start: 600 mg SC x1 on day 1, then 300 mg SC every other week
- [12 yo and older]
- Dose: 300 mg SC every other week; Start: 600 mg SC x1 on day 1, then 300 mg SC every other week
chronic rhinosinusitis w/ nasal polyps, maintenance tx
- [12 yo and older]
- Dose: 300 mg SC every other week
eosinophilic esophagitis
- [1 yo and older, 15-29 kg]
- Dose: 200 mg SC every other week
- [1 yo and older, 30-39 kg]
- Dose: 300 mg SC every other week
- [1 yo and older, >40 kg]
- Dose: 300 mg SC qwk
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- pts <2 yo (pen form)
- helminth infection
- status asthmaticus
- asthma, acute
- bronchospasm, acute
- COPD, acute
- avoid: abrupt corticosteroid D/C
Drug Interactions .
Overview
dupilumab
IL-4 antagonist
- immunosuppressive effects
Contraindicated
- adenovirus vaccine, live
- BCG live intravesical
- chikungunya vaccine, live
- cholera vaccine, live
- dengue vaccine, live
- influenza nasal vaccine, live
- measles/mumps/rubella vaccine, live
- rotavirus vaccine, live
- smallpox vaccine, live
- talimogene laherparepvec
- typhoid vaccine, live
- varicella vaccine, live
- yellow fever vaccine, live
Avoid/Use Alternative
- abrocitinib
- anifrolumab
- cladribine oral
- deuruxolitinib
- etrasimod
- infliximab
- natalizumab
- pimecrolimus topical
- rabies vaccine
- ritlecitinib
- ruxolitinib topical
- upadacitinib
Monitor/Modify Tx
- anthrax vaccine
- carfilzomib
- chikungunya vaccine
- COVID-19 vaccine
- diphtheria/tetanus vaccine
- diphtheria/tetanus/pertussis vaccine
- ebola vaccine, live
- everolimus
- Haemophilus b vaccine
- hepatitis A vaccine
- hepatitis B vaccine
- human papillomavirus vaccine
- influenza H5N1 vaccine
- influenza vaccine
- Japanese encephalitis vaccine
- meningococcal vaccine
- pneumococcal vaccine
- poliovirus vaccine
- respiratory syncytial virus vaccine
- sipuleucel-T
- smallpox/mpox vaccine, live
- temsirolimus
- tick-borne encephalitis vaccine
- typhoid vaccine
Caution Advised
- abatacept
- abemaciclib
- acalabrutinib
- adalimumab
- afamitresgene autoleucel
- aldesleukin
- alemtuzumab
- anakinra
- anti-thymocyte globulin
- atidarsagene autotemcel
- avacopan
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- baricitinib
- basiliximab
- beclomethasone inhaled
- beclomethasone nasal
- belatacept
- belimumab
- belinostat
- bendamustine
- betamethasone
- bimekizumab
- blinatumomab
- bortezomib
- brentuximab vedotin
- brexucabtagene autoleucel
- brodalumab
- budesonide
- budesonide inhaled
- budesonide nasal
- budesonide rectal
- busulfan
- cabazitaxel
- canakinumab
- carboplatin
- carmustine
- certolizumab pegol
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- clobetasol ophthalmic
- clofarabine
- copanlisib
- corticotropin
- cortisone
- crovalimab
- cyclophosphamide
- cyclosporine
- cytarabine
- dactinomycin
- danicopan
- daratumumab
- daunorubicin
- decitabine
- deflazacort
- deucravacitinib
- dexamethasone
- dexamethasone ophthalmic
- difluprednate ophthalmic
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- doxorubicin
- duvelisib
- eculizumab
- efgartigimod alfa
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- epirubicin
- eribulin
- etanercept
- etoposide
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- flunisolide nasal
- fluocinolone intravitreal
- fluorometholone ophthalmic
- fluorouracil
- fluticasone furoate
- fluticasone propionate
- fruquintinib
- gemcitabine
- gemtuzumab ozogamicin
- glofitamab
- golimumab
- guselkumab
- hydrocortisone
- hydrocortisone ophthalmic
- hydroxyurea
- ibritumomab tiuxetan
- ibrutinib
- idarubicin
- idecabtagene vicleucel
- idelalisib
- ifosfamide
- inebilizumab
- inotuzumab ozogamicin
- iptacopan
- irinotecan
- isatuximab
- ixabepilone
- ixekizumab
- lebrikizumab
- leflunomide
- lenalidomide
- lifileucel
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- loteprednol ophthalmic
- lymphocyte immune globulin, anti-thymocyte globulin
- melphalan
- mercaptopurine
- methotrexate
- methylprednisolone
- mirikizumab
- mitoxantrone
- mogamulizumab
- momelotinib
- mometasone implant
- mometasone inhaled
- mometasone nasal
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- nadofaragene firadenovec intravesical
- nelarabine
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- omacetaxine mepesuccinate
- oxaliplatin
- ozanimod
- paclitaxel
- panobinostat
- pegcetacoplan
- pentostatin
- pirtobrutinib
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- pozelimab
- prednisolone
- prednisolone ophthalmic
- prednisone
- procarbazine
- quizartinib
- ravulizumab
- regorafenib
- rilonacept
- risankizumab
- rituximab
- ropeginterferon alfa-2b
- rozanolixizumab
- ruxolitinib
- sarilumab
- satralizumab
- secukinumab
- selinexor
- siltuximab
- siponimod
- sirolimus
- sirolimus albumin-bound
- spesolimab
- sulfasalazine
- sutimlimab
- tacrolimus
- tafasitamab
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- teplizumab
- teriflunomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- tocilizumab
- tofacitinib
- topotecan
- tralokinumab
- triamcinolone
- tuberculin purified protein derivative
- ublituximab
- ustekinumab
- vamorolone
- vedolizumab
- venetoclax
- vilobelimab
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanubrutinib
- zilucoplan
Adverse Reactions .
Serious Reactions
- hypersensitivity rxn
- anaphylaxis
- angioedema
- serum sickness
- serum sickness-like rxn
- keratitis
- helminth infection (peds pts)
- arthralgia, severe
- cholecystitis
Common Reactions
- injection site rxn
- conjunctivitis
- URI
- eosinophilia
- nasopharyngitis
- headache
- hand-foot-mouth dz (atopic dermatitis use in pts <6 yo)
- back pain
- keratitis
- herpes viral infection
- diarrhea
- arthralgia
- myalgia
- dizziness
- UTI
- helminth infection (peds pts)
- oropharyngeal pain
- gastritis
- ocular pruritus
- dry eyes
- skin papilloma (atopic dermatitis use in pts <6 yo)
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; inadequate human data available, though likely to cross placenta based on human data w/ other monoclonal antibodies; no known risk of teratogenicity or embryo-fetal toxicity based on animal data at up to 10x recommended human dose
Pregnancy Registry
enroll pts or encourage pts to enroll in MotherToBaby Pregnancy Study at 1-877-311-8972 or www.mothertobaby.org/ongoing-study/dupixent/
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: catabolism; CYP450: unknown
Excretion: unknown; Half-life: unknown
Subclass: Atopic Dermatitis, Systemic Nonsteroidal Agents ; Interleukin-4/13 (IL-4/13) Antagonists
Mechanism of Action
binds to interleukin-4 receptor alpha subunit and inhibits interleukin-4 and interleukin-13 cytokine-induced responses incl. release of pro-inflammatory cytokines, chemokines, nitric oxide, and IgE (monoclonal antibody)
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.